PYX-201

Pyxis Oncology, Inc · Phase 1 active Small molecule

At a glance

Generic name	PYX-201
Sponsor	Pyxis Oncology, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of PYX-201 in Advanced Solid Tumors (PHASE1)
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PYX-201 CI brief — competitive landscape report
PYX-201 updates RSS · CI watch RSS
Pyxis Oncology, Inc portfolio CI